Positive results for a cat allergy vaccine have been released by HydroPet AG -- a biotechnology company based in Zürich, Switzerland. Dubbed 'HypoCat,' the innovation is said to be "life-changing" if successfully implemented.
The cat allergy vaccine is to be administered to one's feline companion. During its clinical trials, HypoCat has proven to proactively produce a high level of antibodies that successfully neutralize the Fel d 1 allergen -- the culprit behind the sensitivity. HypoPet AG's study strongly suggests that the medication will reduce the risk of allergic reactions in humans. This includes symptoms such as "chronic breathing problems, shortness of breath, rashes, and severe asthma."
The company has plans to release the cat allergy vaccine in the European and North American markets.
Photo Credits: HypoCat AG